Karyopharm Prelim Data in Overall Survival in Selinexor-Treated Patients with Endometrial Cancer

 Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival  (OS) Regardless of Mismatched Repair Status (MMR)

Median OS Not Reached for Selinexor-Treated Patients Who are TP53 Wild-Type pMMR

https://www.prnewswire.com/news-releases/karyopharm-announces-new-preliminary-data-in-overall-survival-os-in-selinexor-treated-patients-with-advanced-or-recurrent-tp53-wild-type-endometrial-cancer-as-part-of-pre-specified-exploratory-subgroup-analysis-of-the-siendo-stu-301977796.html